Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ontorpacept + doxorubicin
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Ontorpacept + doxorubicin is a combination therapy evaluated primarily for advanced leiomyosarcoma and other soft tissue sarcomas. Ontorpacept (TTI-621) is a recombinant fusion protein that acts as a CD47-blocking agent, designed to enhance anti-tumor immune responses by inhibiting the "don't eat me" signal on cancer cells, thereby promoting phagocytosis by macrophages. Doxorubicin is an anthracycline chemotherapy agent that intercalates DNA, inhibits topoisomerase II, and prevents cancer cell replication. The rationale for the combination is that ontorpacept may enhance the effectiveness of doxorubicin by modulating the tumor microenvironment and stimulating immune-mediated tumor cell clearance, complementing the direct cytotoxic effect of doxorubicin. This drug combination was under development by Trillium Therapeutics (acquired by Pfizer) but associated clinical trials have been terminated for administrative reasons, not for safety concerns[1][3][5].
- Brand names
- Adriamycin + TTI-621
- Other names
- ontorpacept + Adriamycin
02
Targets
DNATOP2A (DNA topoisomerase II)SIRPA (Signal-regulatory protein alpha)CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on ontorpacept + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ontorpacept + doxorubicin.